SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of ...

BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

PRAGUE and LONDON--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug ...

SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO Biotech, a ...

PRAGUE, Czech Republic and LONDON, UK I March 03, 2025 I SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel ...

Cat# sc-8426 Formulation: liquid, PBS, gelatin Reactivity: Reacts in: Human, Mouse, Rat ...

Cat# sc-59778 Formulation: liquid, PBS, gelatin Reactivity: Reacts in: Mouse ...